Home » Market News » DirectorsTalk Highlights » Study Looks at Age of Lupus Diagnosis and Impact on Marital Status
Immupharma Plc

Study Looks at Age of Lupus Diagnosis and Impact on Marital Status

New research from Quebec suggests women with lupus are less likely to be married compared to the general population, particularly those who were diagnosed before the age of 30. Marital status was especially low among women with childhood onset lupus (cSLE).

The study assessed marital status among 382 people with lupus (349 females and 33 males) and compared participants with the general population based on their gender and age of lupus onset. The researchers found one-third of women with cSLE were married or in common-law marriages, which was 28% lower than their general population counterparts. Additionally, 50% of women diagnosed between age 18 and 30 were married or in common-law marriages, which was 14% less than general population rates. Researchers did not find a significant difference for women diagnosed after age 30 or for males, however.

Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.